Pasar al contenido principal

DISEÑO DE NANOPARTICULAS DE POLI (BETA AMINOESTER) CARGADAS CON ARNM CON IMPERMEABILIDAD PLACENTARIA PARA EL TRATAMIENTO SEGURO DE CANCER EN MUJERES EMBARAZADAS

PID2024-159704OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para la Investigación y el Desarrollo Experimental
Subprograma Subprograma Estatal de Generación de Conocimiento Científico-Técnico y Desarrollo Experimental
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2024
Plan Estatal 2024-2027 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSITAT RAMON LLULL, FUNDACIO PRIVADA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Balancing stability and cellular interaction in surface-engineered small extracellular vesicles for pulmonary delivery

  • Gomez Sanchez, Jose
  • Leivar, Pablo
  • Pinto, Soraia
  • Almeida, Helena
  • Artigues Cladera, Margalida
  • Sarmento, Bruno
  • Lecina, Martí
  • Fornaguera, Cristina
Small extracellular vesicles (sEVs) are emerging as promising nanocarriers for non-invasive pulmonary drug delivery, yet their effectiveness is limited by sequential barriers imposed by airway mucus and the pulmonary epithelium-endothelium interface. Here, we investigated how post-secretory surface engineering with exogenous phospholipids modulates sEVs transport across lung-relevant barriers. eGFP-CD81 engineered sEVs were post-secretory modified at their surface composition using different lipid-to-vesicle ratios of either the zwitterionic lipid 1,2- Dilauroyl-sn-glycero-3-phosphocholine (DLPC) or the PEGylated lipid 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) -PEG(5000) - Azide (DPA). Both modifications enabled controlled tuning of surface charge and colloidal stability without altering vesicle size at optimized lipid-to-vesicle ratios, although excessive DPA induced aggregation. The physicochemical properties and transport behaviour of engineered sEVs were evaluated in a reconstituted mucin gel and a 3D pulmonary epithelial-endothelial co-culture model. In mucin-containing medium, lipid-engineered sEVs showed enhanced diffusion compared with unmodified vesicles, with DLPC at a 30,000:1 ratio providing the highest cumulative permeability, sustained apparent permeability coefficients, and more diffusive motion profiles, as confirmed by multiple particle tracking. In the 3D co-culture, the same modification achieved the greatest cumulative permeability and basolateral accumulation, indicating efficient transcellular passage, while DPA-functionalized vesicles displayed moderate permeability and predominant retention at the apical epithelial layer. Through fluorescently-labelling EVs, we confirmed that all formulations were internalized by apical cells, but only DLPC-engineered sEVs reached detectable levels in basolateral cells. Neither DLPC nor DPA affected cell viability or barrier morphology. Overall, our results identify DLPC at 30,000:1 as a lead formulation that balances mucus penetration and efficient crossing of the pulmonary barrier, while DPA is better suited for applications requiring strong epithelial engagement. Our findings highlight rational phospholipid engineering as a powerful approach to tailor sEVs-based nanomedicines for pulmonary delivery., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Covalent functionalization of polymeric nanoparticles prepared from nano-emulsion templates for gene silencing and antioxidant delivery at neuronal level

  • Bel Esteve, Marta
  • Carrasco, Marc
  • Moral, Nuria
  • Aviñó, Ana
  • Fàbrega, Carme
  • eritja, ramon
  • del Río, José Antonio
  • Duran, Jordi
  • Fornaguera, Cristina
  • Rodriguez-Abreu, Carlos
  • Grijalvo, Santiago
Poly(lactic-co-glycolic acid) (PLGA)-based polymeric nanoparticles (PLGA NPs) have proven to be effective as potential drug delivery systems. The presence of carboxylate groups on their surface facilitates the development of multifunctional NPs enhancing therapeutic efficacy through synergetic effects. Our study describes the preparation of PLGA NPs using oil-in-water polymeric nano-emulsions, generated via a phase inversion composition low-energy emulsification method. Rosmarinic acid (RA), a phytochemical with neuroprotective effects, and an antisense oligonucleotide (ASO) were selected respectively as a phytochemical to be entrapped and as a ligand to decorate the surface of PLGA nanoparticles respectively, aiming to enhance ASO delivery to neuronal cells. Physicochemical characterization confirmed that RA and ASO incorporation preserved colloidal stability, with no adverse effect on particle size, surface charge, or morphology. In vitro-controlled release experiments showed a cumulative RA release of ca. 12% over 24 h governed by a semi-Fickian diffusion mechanism after adjusting to different equation models. Importantly, RA entrapment displayed measurable radical scavenging capacity, leading to a EC50 of 76 ± 0.9 μg·mL−1. Cell culture experiments confirmed biocompatibility in both a non-cancer cell line (HEK293) and neuroblastoma cell model (SH-SY5Y). Uptake studies revealed efficient internalization of PLGA NPs by SH-SY5Y cells and primary murine neurons, promoting gene silencing of luciferase expression (53.7 ± 7.9%). Together, these results show a modular PLGA nanoplatform that enables the simultaneous incorporation of an antioxidant payload and a covalently grafted antisense oligonucleotide, allowing independent assessment of redox modulation and gene silencing in neuronal models., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Balancing stability and cellular interaction in surface-engineered small extracellular vesicles for pulmonary delivery

  • Gomez Sanchez, Jose
  • Leivar, Pablo
  • Pinto, Soraia
  • Almeida, Helena
  • Artigues Cladera, Margalida
  • Sarmento, Bruno
  • Lecina, Martí
  • Fornaguera, Cristina
Small extracellular vesicles (sEVs) are emerging as promising nanocarriers for non-invasive pulmonary drug delivery, yet their effectiveness is limited by sequential barriers imposed by airway mucus and the pulmonary epithelium-endothelium interface. Here, we investigated how post-secretory surface engineering with exogenous phospholipids modulates sEVs transport across lung-relevant barriers. eGFP-CD81 engineered sEVs were post-secretory modified at their surface composition using different lipid-to-vesicle ratios of either the zwitterionic lipid 1,2- Dilauroyl-sn-glycero-3-phosphocholine (DLPC) or the PEGylated lipid 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) -PEG(5000) - Azide (DPA). Both modifications enabled controlled tuning of surface charge and colloidal stability without altering vesicle size at optimized lipid-to-vesicle ratios, although excessive DPA induced aggregation. The physicochemical properties and transport behaviour of engineered sEVs were evaluated in a reconstituted mucin gel and a 3D pulmonary epithelial-endothelial co-culture model. In mucin-containing medium, lipid-engineered sEVs showed enhanced diffusion compared with unmodified vesicles, with DLPC at a 30,000:1 ratio providing the highest cumulative permeability, sustained apparent permeability coefficients, and more diffusive motion profiles, as confirmed by multiple particle tracking. In the 3D co-culture, the same modification achieved the greatest cumulative permeability and basolateral accumulation, indicating efficient transcellular passage, while DPA-functionalized vesicles displayed moderate permeability and predominant retention at the apical epithelial layer. Through fluorescently-labelling EVs, we confirmed that all formulations were internalized by apical cells, but only DLPC-engineered sEVs reached detectable levels in basolateral cells. Neither DLPC nor DPA affected cell viability or barrier morphology. Overall, our results identify DLPC at 30,000:1 as a lead formulation that balances mucus penetration and efficient crossing of the pulmonary barrier, while DPA is better suited for applications requiring strong epithelial engagement. Our findings highlight rational phospholipid engineering as a powerful approach to tailor sEVs-based nanomedicines for pulmonary delivery., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Covalent functionalization of polymeric nanoparticles prepared from nano-emulsion templates for gene silencing and antioxidant delivery at neuronal level

  • Bel Esteve, Marta
  • Carrasco, Marc
  • Moral, Nuria
  • Aviñó, Ana
  • Fàbrega, Carme
  • eritja, ramon
  • del Río, José Antonio
  • Duran, Jordi
  • Fornaguera, Cristina
  • Rodriguez-Abreu, Carlos
  • Grijalvo, Santiago
Poly(lactic-co-glycolic acid) (PLGA)-based polymeric nanoparticles (PLGA NPs) have proven to be effective as potential drug delivery systems. The presence of carboxylate groups on their surface facilitates the development of multifunctional NPs enhancing therapeutic efficacy through synergetic effects. Our study describes the preparation of PLGA NPs using oil-in-water polymeric nano-emulsions, generated via a phase inversion composition low-energy emulsification method. Rosmarinic acid (RA), a phytochemical with neuroprotective effects, and an antisense oligonucleotide (ASO) were selected respectively as a phytochemical to be entrapped and as a ligand to decorate the surface of PLGA nanoparticles respectively, aiming to enhance ASO delivery to neuronal cells. Physicochemical characterization confirmed that RA and ASO incorporation preserved colloidal stability, with no adverse effect on particle size, surface charge, or morphology. In vitro-controlled release experiments showed a cumulative RA release of ca. 12% over 24 h governed by a semi-Fickian diffusion mechanism after adjusting to different equation models. Importantly, RA entrapment displayed measurable radical scavenging capacity, leading to a EC50 of 76 ± 0.9 μg·mL−1. Cell culture experiments confirmed biocompatibility in both a non-cancer cell line (HEK293) and neuroblastoma cell model (SH-SY5Y). Uptake studies revealed efficient internalization of PLGA NPs by SH-SY5Y cells and primary murine neurons, promoting gene silencing of luciferase expression (53.7 ± 7.9%). Together, these results show a modular PLGA nanoplatform that enables the simultaneous incorporation of an antioxidant payload and a covalently grafted antisense oligonucleotide, allowing independent assessment of redox modulation and gene silencing in neuronal models., info:eu-repo/semantics/publishedVersion